Skip to main content

Anti-TIF1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma in 1 year: a case report

Abstract

Background

Patients with connective tissue disease, such as dermatomyositis (DM), and positive anti-TIF1γ self-antibodies are commonly diagnosed with malignant tumors as a comorbidity. The relationship between anti-TIF1γ self-antibodies and existing malignant tumors has been confirmed by several reports. However, interstitial pneumonia with autoimmune features (IPAF) cases with a positive anti-TIF1γ self-antibody developing to solid malignant tumors are rarely reported now.

Case presentation

Herein, we presented an IPAF patient with anti-TIF1γ self-antibodies. No evidence of malignant tumors was found at the initial visit. However, the patient had developed stage IVB lung squamous cell carcinoma at the 1-year follow-up review.

Conclusions

Altogether, this report described a rare case of IPAF patient with anti-TIF1γ self-antibodies developed to advanced lung squamous cell carcinoma in 1 year. The present case highlights more frequent imaging examinations to identify the occurrence of malignant tumors as early as possible in IPAF patients with positive anti-TIF1γ self-antibodies.

Peer Review reports

Background

DM patients with positive anti-TIF1γ self-antibodies are commonly diagnosed with malignant tumors as a comorbidity[1,2,3]. The patient we reported was initially diagnosed as an IPAF case with anti-TIF1γ self-antibody. No evidence of malignant tumors was found. However, through the following visiting, we found the patient had developed stage IVB lung squamous cell carcinoma at the 1-year follow-up review. Recently, more and more rheumatologists and respiratory physicians start to pay more attention to the routine screening of solid tumors in DM patients with anti-TIF1γ self-antibody. However, the follow-up visiting of these patients with no tumor evidence in the initial screening is far from enough. Through this case report, we call for more attention to the follow-up radiologic imaging of these patients.

Case presentation

A 65-year-old Chinese man presented with gradually worsening cough and shortness of breath for 1 year. Throughout the course of the disease, the patient had no symptoms of hemoptysis or chest pain. He occasionally experienced dry mouth and dry eyes but no itchy skin, desquamation or joint pain. He was admitted to the respiratory department on July 19th, 2019, for further diagnosis and assessment. The patient had normal skin and mucosa, with no rash or scaling. No special past histories and family inherited diseases were reported. Velcro rales could be heard in both lower lungs on physical examination. An initial chest CT scan was taken and indicated interstitial inflammation and fibrosis in the basal segment of the bilateral lower lobe (Fig. 1). In lung function tests, DLCO suggested a moderate diffusion disorder (54.6 % predictive value).

Fig. 1
figure 1

Initial chest HRCT scan performed on July 19th, 2019. Photos indicate interstitial lung inflammation with imaging features of NSIP

The full blood count, basic metabolic panel, ECG and echocardiography were all normal in this patient. Anti-endothelial cell antibody (AECA) was positive (1:100), but other vasculitis-related self-antibodies were negative. Antinuclear antibody (ANA), anti-CCP, anti-SSA, anti-SSB, Ro-52, anti-nRNP, anti-Sm, anti-Jo1, anti-PM-Scl, anti-Scl-70, and anti-dsDNA antibodies were all negative. However, the myositis antibody panel showed a positive test for the anti-TIF1γ self-antibody.

According to the patient’s positive anti-TIF1γ self-antibody findings and NSIP chest CT manifestation without any clinical signs of DM, such as rash or skin lesions, we diagnosed this patient with IPAF. Subsequently, this patient underwent PET-CT scans and serum tumor marker analysis to search for evidence of potential solid tumors [4]. However, no evidence of any tumor was found. After excluding contraindications, the patient was given oral prednisone (30 mg) once a day and pirfenidone (600 mg) three times per day, respectively.

The patient’s symptoms were not significantly aggravated after these treatments. However, the patient did not return to the hospital for follow-up reviews because of the COVID-19 epidemic in China at the end of 2019. Nearly 1 year later, the patient was admitted to the respiratory department on August 6th, 2020, presenting with aggravated shortness of breath over the previous 3 months. An enhanced chest CT scan showed an irregularly shaped nodule located on the anterior segment of the right upper lobe. Enlarged mediastinal lymph nodes were visible in the right hilum and mediastinum (Fig. 2). Enhanced CT of the abdomen revealed bilateral adrenal nodules, and brain MRI revealed multiple metastatic nodules in the bilateral cerebral hemispheres (Fig. 2). These imaging findings suggested the possibility of malignant lung tumors with multiple metastases. Following CT-guided percutaneous lung biopsy of the right lung nodule and needle aspiration of mediastinal lymph nodes under endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), this patient was definitively diagnosed with right lung squamous carcinoma with mediastinal lymph node, brain and adrenal glands metastasis (Fig. 3).

Fig. 2
figure 2

Imaging findings and EBUS-TBNA performed in August 2020 during the second admission of this patient. a–e Enhanced chest HRCT showed a newly emerged nodule located on the anterior segment of the right upper lobe that was not present on the HRCT performed in 2019. The mediastinal window suggested enlarged mediastinal and hilar lymph nodes. f Enhanced CT of the abdomen revealed bilateral adrenal nodules. g–h Brain MRI revealed multiple metastatic nodules in the bilateral cerebral hemispheres. i EBUS-TBNA performed on the N7 group of enlarged mediastinal lymph nodes

Fig. 3
figure 3

Hematoxylin and eosin sections (original magnification ×200). Slices with H&E staining were observed under the NIKON TE2000-U microscope(10×eyepiece, 20×objective lens). Photos were captured through a CCD digital camera involved in NIKON TE2000-U microscopic platform. Typical photos were recorded by NIKON NIS-Elements software V4.2. a CT-guided percutaneous lung biopsy. The tissue cut by fine needle was composed of atypical epithelioid neoplasm cells organized in a squamous carcinoma pattern. b EBUS-TBNA. Squamous cell clusters mixed in the mediastinal lymph node tissue of the N7 group aspirated by the fine needle

Discussion and conclusion

Transcriptional intermediary factor 1γ (TIF1γ), an E3 ubiquitin ligase family member, plays a crucial role in regulating TGF-β/Smad signaling in different cellular contexts [5, 6]. Based on its role in this signaling, studies on TIF1γ performed in the last decade have demonstrated a relationship between decreased TIF1γ and cancer [7, 8]. According to past studies, anti-TIF1γ antibodies are detected in approximately 20 % of adult DM patients [9]. Among them, 60–80 % have been diagnosed with malignant tumors as a comorbidity with DM [10]. In our reported case, the patient’s symptoms and physical signs did not meet the criteria for initial diagnosis with DM, so the patient was diagnosed with IPAF. When we first detected the anti-TIF1γ self-antibody, PET-CT scanning and tumor biomarker detection were performed. However, there was no visible evidence of solid tumors. Unfortunately, the patient was diagnosed with stage IVB lung squamous carcinoma at the 1-year follow-up review, despite regular IPAF treatments. Some previous studies have also proposed the importance of follow-up chest CT in assessing the pulmonary status of ILD patients. However, they have not given the exact CT follow-up interval time [11, 12]. Based on this case, we suggest that IPAF patients with positive anti-TIF1γ self-antibodies might need more frequent imaging examinations to identify the occurrence of malignant tumors as early as possible.

Availability of data and materials

The data that support this case report are available from the corresponding author on reasonable request, since respecting the Ethics Committee to protect patient confidentiality.

Abbreviations

CTD:

Connective tissue disease

DM:

Dermatomyositis

IPAF:

Interstitial pneumonia with autoimmune features

AECA:

Anti-endothelial cell antibody

EBUS-TBNA:

Endobronchial ultrasound-guided transbronchial needle aspiration

References

  1. Czerwinska P, Wlodarczyk NA, Jaworska AM, Mackiewicz AA. The association between TIF1 family members and cancer stemness in solid tumors. Cancers (Basel). 2021;13(7):1528.

    Article  Google Scholar 

  2. Varedi D, Frigerio A, Scaife C, Hull C. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor. Dermatol Online J. 2019;25(3):13030.

    PubMed  Google Scholar 

  3. Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 2012;64(2):346–9.

    Article  Google Scholar 

  4. Yu C, Ding Z, Liang H, Zhang B, Chen X. The roles of TIF1gamma in cancer. Front Oncol. 2019;9:979.

    Article  Google Scholar 

  5. De Vooght J, Vulsteke JB, De Haes P, Bossuyt X, Lories R, De Langhe E. Anti-TIF1-gamma autoantibodies: warning lights of a tumour autoantigen. Rheumatology. 2020;59(3):469–77.

    Article  Google Scholar 

  6. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008;99(11):2107–12.

    CAS  Article  Google Scholar 

  7. Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-beta-induced epithelial-mesenchymal transition and metastasis by controlling TIF1gamma in non-small cell lung cancer. Mol Cancer. 2018;17(1):140.

    Article  Google Scholar 

  8. Wang L, Yang H, Lei Z, Zhao J, Chen Y, Chen P, Li C, Zeng Y, Liu Z, Liu X, et al. Repression of TIF1gamma by SOX2 promotes TGF-beta-induced epithelial-mesenchymal transition in non-small-cell lung cancer. Oncogene. 2016;35(7):867–77.

    CAS  Article  Google Scholar 

  9. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513–22.

    CAS  Article  Google Scholar 

  10. Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol. 2017;8:992.

    Article  Google Scholar 

  11. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.

    Article  Google Scholar 

  12. Kishaba T. Practical management of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(2):90–8.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank the patient who contributed to this report, as well as the staff of each department.

Funding

Funding was provided by National Nature Science Foundation of China (No. 81500015) and the Foundation of Chongqing Medical University for COVID-19(X2821) for patient’s follow-up review.

Author information

Authors and Affiliations

Authors

Contributions

The authors all cared for the patient and contributed to organizing the report. J.X and B.L drafted the case report and were responsible for the data and figures. R.X designed the report and was responsible for the intellectual content of the report. J.H and X.D performed the biopsy, data collecting and language modifying. J.H and X.D substantively revised the report. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rui Xu.

Ethics declarations

Ethics approval and consent to participate

This report was approved by the Ethical Committee of The Second Affiliated Hospital of Chongqing Medical University.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and accompanying clinical data. A copy of the written consent in Chinese language is available for review by the editor of this journal.

Competing interests

There are no conflicts of interest to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xie, Jj., Li, B., Xu, R. et al. Anti-TIF1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma in 1 year: a case report. BMC Pulm Med 21, 204 (2021). https://doi.org/10.1186/s12890-021-01570-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-021-01570-y

Keywords

  • Anti-TIF1γ self-antibody
  • IPAF
  • Lung carcinoma
  • Squamous cell carcinoma
  • Case report